MPM, DCVC Bio back $53M round for a bold concept: Let patients make their own CAR-T in vivo
The onerous process of making a personalized CAR-T — one that involves extracting cells from patients, engineering and then injecting them back — is one of the defining features of the first generation of engineered cell therapies. It’s partly why the treatments are so expensive; it’s also an inspiration for new allogeneic approaches that promise to be faster and cheaper.
But a biotech startup in Seattle wants to go further.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.